Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer (Oscillate)

被引：0

作者：

Mersiades, Antony ^{[1
]}

Pavlakis, Nick ^{[2
]}

Kao, Steven ^{[3
]}

John, Tom ^{[4
]}

Lee, Chee Khoon ^{[1
,5
]}

Dawson, Sarah-Jane ^{[6
]}

Wong, Stephen ^{[6
]}

Tan, Lavinia ^{[6
]}

Yip, Sonia ^{[1
]}

Brown, Chris ^{[1
]}

Livingstone, Ann ^{[1
]}

Cheung, Yvonne ^{[1
]}

Jurkovic, Hannora ^{[1
]}

Stockler, Martin ^{[1
]}

机构：

[1] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia

[2] Royal North Shore Hosp, Dept Med Oncol, Sydney, NSW, Australia

[3] Chris OBrien Lifehouse, Camperdown, NSW, Australia

[4] Olivia Newton John Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[5] St George Hosp, Dept Med Oncol, Sydney, NSW, Australia

[6] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

421

引用

页码：199 / 200

页数：2

共 50 条

[41] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
Choo, Joan Rou-En
Tan, Chee-Seng
Soo, Ross A.
TARGETED ONCOLOGY, 2018, 13 (02) : 141 - 156
[42] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
Joan Rou-En Choo
Chee-Seng Tan
Ross A. Soo
Targeted Oncology, 2018, 13 : 141 - 156
[43] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
Alsharedi, M.
Bukamur, H.
Elhamdani, A.
DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
[44] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
Meinrenken, Susanne
PNEUMOLOGIE, 2018, 72 (04): : 246 - 246
[45] EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
Sonoda, Tomoaki
Nishikawa, Shingo
Sakakibara, Rie
Saiki, Masafumi
Ariyasu, Ryo
Koyama, Junji
Kitazono, Satoru
Yanagitani, Noriko
Horiike, Atsushi
Ohyanagi, Fumiyoshi
Ninomiya, Hironori
Ishikawa, Yuichi
Nishio, Makoto
RESPIRATORY MEDICINE CASE REPORTS, 2018, 24 : 19 - 21
[46] Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer
Kim, Chul
Liu, Stephen V.
Subramaniam, Deepa Suresh
Giaccone, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[47] The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
Akihiro Yoshimura
Tadaaki Yamada
Naoko Okura
Takayuki Takeda
Wataru Furutani
Yutaka Kubota
Shinsuke Shiotsu
Osamu Hiranuma
Naoya Nishioka
Yusuke Chihara
Nobuyo Tamiya
Yoshiko Kaneko
Junji Uchino
Koichi Takayama
BMC Cancer, 18
[48] The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
Yoshimura, Akihiro
Yamada, Tadaaki
Okura, Naoko
Takeda, Takayuki
Furutani, Wataru
Kubota, Yutaka
Shiotsu, Shinsuke
Hiranuma, Osamu
Nishioka, Naoya
Chihara, Yusuke
Tamiya, Nobuyo
Kaneko, Yoshiko
Uchino, Junji
Takayama, Koichi
BMC CANCER, 2018, 18
[49] PD-L1 expression influenced by osimertinib treatment in advanced EGFR T790M-positive non-small cell lung cancer patients
Yu, Y.
Xia, L.
Zhou, J.
Wang, K.
Zhang, Y.
Zhang, C.
Liu, A.
Fan, Y.
Chang, J.
Wang, L.
Liu, Y.
Lu, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S778 - S778
[50] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status
Nakashima, Kazuhisa
Kimura, Madoka
Akamatsu, Hiroaki
Daga, Haruko
Imai, Hisao
Taira, Tetsuhiko
Ko, Ryo
Hisamatsu, Yasushi
Nishino, Kazumi
Sugimoto, Takeya
Miyashita, Yosuke
Takahashi, Toshiaki
Kumagai, Toru
Yamamoto, Nobuyuki
Murakami, Haruyasu
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (07) : 671 - 675

← 1 2 3 4 5 →